Type 2 diabetes is a progressive condition in which the body becomes resistant to the normal effects of insulin and/or gradually loses the capacity to produce enough insulin in the pancreas. We do not know what causes type 2 diabetes. Type 2 diabetes is associated with modifiable lifestyle risk factors. Type 2 diabetes also has strong genetic and family related risk factors.
The dramatic increase in the prevalence, progressive nature and diagnosis of type 2 diabetes is the main driver of this rapid growth rate. The rise in disease-related comorbidities has also fuelled a more aggressive approach to treatment, including the use of multiple-drug therapies.

The global Type 2 Diabetes market was valued at US$ XX million in 2019 and is expected to reach US$ XX million by the end of 2026, growing at a CAGR of XX% during 2021-2026.
This report focuses on Type 2 Diabetes volume and value at the global level, regional level and company level. From a global perspective, this report represents overall Type 2 Diabetes market size by analysing historical data and future prospect. Regionally, this report focuses on several key regions: North America, Europe, Asia-Pacific, Latin America and Middle East & Africa.

Global Type 2 Diabetes Market: Segment Analysis
The research report includes specific segments by region (country), by company, by Type and by Application. This study provides information about the sales and revenue during the historic and forecasted period of 2016 to 2027. Understanding the segments helps in identifying the importance of different factors that aid the market growth.

Segment by Type
Insulins
DPP-4 Inhibitors
GLP-1 Receptor Agonists
SGLT-2 Inhibitors

Segment by Application
Drugstore
Hospital
Others

By Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Indonesia
Thailand
Malaysia
Philippines
Vietnam
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
U.A.E

By Company
Novo Nordisk
Sanofi
Merck
Eli Lily
AstraZeneca
Astellas Pharma
Daiichi Sankyo
Biocon
Boehringer Ingelheim